Compare Novo Nordisk A/S (NVO) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Xpeng Inc - ADR — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: Novo Nordisk A/S is far larger — about 18× Xpeng Inc - ADR's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Xpeng Inc - ADR for 80 Days on average.
| NVO | XPEV | |
|---|---|---|
Market Cap | $165.31B | $9.16B |
Volume | 11,432,838 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $28.07 |
52-Week Low | $35.29 | $9.25 |
Typical Hold Time | 116 Days | 80 Days |
Enterprise Value | $179.56B | $11.09B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
XPeng (XPEV) trades at $9.55, down 0.31% with a bearish technical signal. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a net margin of -4.14%. Recent vehicle deliveries of 41,256 in September 2026 and the upcoming G9L SUV launch at the Paris Motor Show highlight expansion efforts. Analyst consensus is bullish with a $17.55 price target, though earnings misses in Q1 and Q2 2026 raise execution concerns.
The stock presents a high-risk, high-reward opportunity. Significant revenue growth and analyst optimism are offset by persistent losses and competitive pressures. Key catalysts include successful global expansion and profitability improvements, while risks involve execution missteps and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
